Panel of ALS Researchers to Present and Consider the Latest Therapeutic Approaches
CAMBRIDGE, Mass., Sept. 24 /PRNewswire-USNewswire/ -- The ALS Therapy Development Institute (ALS TDI) announced the line-up for its upcoming, annual ALS research symposium, part of the fourth annual ALS TDI Leadership Summit. The symposium will take place this October 20th at the Beacon Hill Holiday Inn in Boston, Mass. A diverse panel of scientists will provide presentations on the development of effective treatments, or a cure, for amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease). After each presentation, audience members are invited to offer comments and ask questions regarding the research. Several of the guest speakers will participate in a panel discussion to take place between the morning and afternoon sessions. The entire event is being offered free of charge by ALS TDI.
"There is a need in the ALS community for openness and directness when it comes to describing what is done with all the monies donated for research. Providing unbiased access to information and researchers is one of the pillars of the ALS TDI philosophy. This annual event provides a unique setting for patients and researchers to connect in pursuit of a shared goal," said John McCarty, Ph.D., Director of Therapeutic Investigation at ALS TDI.
The following is a list of confirmed researchers and proposed
-- "Our Plan, Our Progress, Your Lab," Sean Scott, President, ALS
TDI, Cambridge, Mass.;
-- "The MDA Commitment," Sharon Hesterlee, Ph.D., Vice President
for Translational Research, Muscular Dystrophy Association, Tucson,
-- "Towards defining the molecular basis of ALS: clues from
TDP-43," Michael J. Strong, M.D., Co-Chair, Department of Clinical
Neurological Sciences, Arthur J. Hudson Chair in ALS Research, London
Health Sciences Centre, Londo
|SOURCE ALS Therapy Development Institute|
Copyright©2008 PR Newswire.
All rights reserved